Hiroyuki Suganuma

Dr. Hiroyuki Suganuma

Innovation Division, KAGOME CO., LTD.,
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
NFNobuo Fuke
Nobuo Fuke
Naoto NagataNaoto Nagata
Naoto Nagata
HSHiroyuki Suganuma
Hiroyuki Suganuma
TOTsuguhito Ota
Tsuguhito Ota
Metabolic endotoxemia is a condition in which blood lipopolysaccharide (LPS) levels are elevated, regardless of the presence of obvious infection. It has been suggested to lead to chronic inflammation-related diseases such as obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), pancreatitis, amyotrophic lateral sclerosis, and Alzheimer’s disease. In addition, it has attracted attention as a target for the prevention and treatment of these chronic diseases. As metabolic endotoxemia was first reported in mice that were fed a high-fat diet, research regarding its relationship with diets has been actively conducted in humans and animals. In this review, we summarize the relationship between fat intake and induction of metabolic endotoxemia, focusing on gut dysbiosis and the influx, kinetics, and metabolism of LPS. We also summarize the recent findings about dietary factors that attenuate metabolic endotoxemia, focusing on the regulation of gut microbiota. We hope that in the future, control of metabolic endotoxemia using dietary factors will help maintain human health.

7 February 2003 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
TMTatsuya Morita
Tatsuya Morita
KJKeiko Jinno
Keiko Jinno
HKHirokazu Kawagishi
Hirokazu Kawagishi
YAYasushi Arimoto
Yasushi Arimoto
HSHiroyuki Suganuma
Hiroyuki Suganuma
KSKimio Sugiyama
Kimio Sugiyama

16 February 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
Naoto NagataNaoto Nagata
Naoto Nagata
LXLiang Xu
Liang Xu
SKSusumu Kohno
Susumu Kohno
YUYusuke Ushida
Yusuke Ushida
YAYudai Aoki
Yudai Aoki
TOTsuguhito Ota
Tsuguhito Ota
Low-grade sustained inflammation links obesity to insulin resistance and nonalcoholic fatty liver disease (NAFLD). However, therapeutic approaches to improve systemic energy balance and chronic inflammation in obesity are limited. Pharmacological activation of nuclear factor (erythroid-derived 2)–like 2 (Nrf2) alleviates obesity and insulin resistance in mice; however, Nrf2 inducers are not clinically available owing to safety concerns. Thus, we examined whether dietary glucoraphanin, a stable precursor of the Nrf2 inducer sulforaphane, ameliorates systemic energy balance, chronic inflammation, insulin resistance, and NAFLD in high-fat diet (HFD)–fed mice. Glucoraphanin supplementation attenuated weight gain, decreased hepatic steatosis, and improved glucose tolerance and insulin sensitivity in HFD-fed wild-type mice but not in HFD-fed Nrf2 knockout mice. Compared with vehicle-treated controls, glucoraphanin-treated HFD-fed mice had lower plasma lipopolysaccharide levels and decreased relative abundance of the gram-negative bacteria family Desulfovibrionaceae in their gut microbiomes. In HFD-fed mice, glucoraphanin increased energy expenditure and the protein expression of uncoupling protein 1 (Ucp1) in inguinal and epididymal adipose depots. Additionally, in this group, glucoraphanin attenuated hepatic lipogenic gene expression, lipid peroxidation, classically activated M1-like macrophage accumulation, and inflammatory signaling pathways. By promoting fat browning, limiting metabolic endotoxemia-related chronic inflammation, and modulating redox stress, glucoraphanin may mitigate obesity, insulin resistance, and NAFLD.

1 January 2000 in Bioscience, Biotechnology, and Biochemistry
Verified
Journal Article
Closed access
ELEun Woo Lee
Eun Woo Lee
KSKazue Shizuki
Kazue Shizuki
SHSatoshi Hosokawa
Satoshi Hosokawa
MSMasami Suzuki
Masami Suzuki
HSHiroyuki Suganuma
Hiroyuki Suganuma
HKHirokazu Kawagishi
Hirokazu Kawagishi
Novel diterpenoids, erinacines H (1) and I (3), were isolated from the cultured mycelia of Hericium erinaceum. The structures of the compounds were determined by interpretation of the spectral data. Erinacine H showed stimulating activity of nerve growth factor (NGF)-synthesis.

29 July 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WYWei Yao
Wei Yao
JZJi-Chun Zhang
Ji-Chun Zhang
TITamaki Ishima
Tamaki Ishima
CDChao Dong
Chao Dong
CYChun Yang
Chun Yang
KHKenji Hashimoto
Kenji Hashimoto
The transcription factor Keap1-Nrf2 system plays a key role in inflammation which is involved in depression. We found lower expression of Keap1 and Nrf2 proteins in the prefrontal cortex (PFC), CA3 and dentate gyrus (DG) of hippocampus in mice with depression-like phenotype compared to control mice. Serum levels of pro-inflammatory cytokines inNrf2knock-out (KO) mice were higher than those of wild-type mice, suggestive of enhanced inflammation in KO mice. Decreased brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-receptor-kinase B (TrkB) signaling in the PFC, CA3 and DG plays a role in the depression-like phenotype ofNrf2KO mice. TrkB agonist 7,8-dihydroxyflavone, but not antagonist ANA-12, produced antidepressant effects inNrf2KO mice, by stimulating TrkB in the PFC, CA3 and DG. Pretreatment with Nrf2 activator sulforaphane (SFN) prevented the depression-like phenotype induced after repeated social defeat stress. Interestingly, dietary intake of 0.1% glucoraphanin (a precursor of SFN) containing food during juvenile and adolescent stages also prevented the depression-like phenotype evoked in adulthood, after repeated social defeat stress. These findings suggest that Keap1-Nrf2 system plays a key role in depression and that dietary intake of SFN-rich food during juvenile stages and adolescence can confer stress resilience in adulthood.

1 January 2017 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
JZJi-Chun Zhang
Ji-Chun Zhang
WYWei Yao
Wei Yao
CDChao Dong
Chao Dong
CYChun Yang
Chun Yang
QRQian Ren
Qian Ren
KHKenji Hashimoto
Kenji Hashimoto